

# AccuPlex™ SARS-CoV-2 in Synthetic Oral Fluid

## ASSAY VERIFICATION AND ONGOING PERFORMANCE MONITORING FOR SALIVA-BASED TESTING

### HIGHLIGHTS

DESIGNED FOR SALIVA  
BASED SARS-COV-2  
ASSAYS

REAL MAMMALIAN  
VIRUS ENABLES FULL  
PROCESS QC FOR  
RT-PCR BASED VIRAL  
DISEASE ASSAYS

NON-INFECTIOUS  
AND REPLICATION  
DEFICIENT; ENSURES  
SAFETY DURING  
ASSAY DEVELOPMENT  
AND END-USER QC  
APPLICATIONS

In support of industry efforts to develop SARS-CoV-2 testing formats compatible with alternative sample types, LGC SeraCare now offers its proprietary AccuPlex SARS-CoV-2 reference material in a synthetic oral fluid matrix. The product is designed to challenge the entire molecular test procedure for oral fluid-based tests, ensuring laboratories can have confidence in their SARS-CoV-2 assay results.

**AccuPlex™ SARS-CoV-2 in Synthetic Oral Fluid** is an ideal research tool for assay developers creating novel saliva-based SARS-CoV-2 assays, as well as a complete quality solution for laboratories employing such tests. The product includes positive vials containing the full SARS-CoV-2 viral genome, and human RNase P sequences to monitor sample collection. The positive material is configured at 3 different concentrations to enable performance evaluation across the assay range and limit of detection studies. Negative material containing only RNase P sequences is also included.

Product Description	Material Number	Pack Size	Concentration	
			SARS-CoV-2	RNase P
AccuPlex™ SARS CoV-2 in Synthetic Oral Fluid	0505-0222	Positive 1 1 x 1 mL	24,000 cp/mL	24,000 cp/mL
		Positive 2 1 x 1 mL	12,000 cp/mL	24,000 cp/mL
		Positive 3 1 x 1 mL	6,000 cp/mL	24,000 cp/mL
		Negative 1 x 1 mL	0 cp/mL	24,000 cp/mL
		Diluent 2 x 1.5 mL	N/A	N/A

*Not for In Vitro Diagnostic Use. Research Use Only.*

**AccuPlex™ SARS-CoV-2 in Synthetic Oral Fluid** can be utilized for assay verification at installation by documenting test performance along the assay's range, enabling laboratories to establish lower limits of detection, perform assay comparisons, and evaluate staff proficiency. The product may also be utilized as a quality tool to measure day-to-day performance of the assay. Additional synthetic oral fluid diluent is included to allow additional dilutions as required.

**For custom requests, please contact [sarscov2@seracare.com](mailto:sarscov2@seracare.com)**

### SARS-COV-2 ACCUPLEX SOLUTION:

- Non-infectious and replication deficient, enables safe handling in contrast to viral samples
- Fully-extractable with a real viral protein coat; superior to "naked" transcribed RNA
- 2 year stability at 2 - 8°C
- Customizable to sequences of interest to meet unique assay design requirements

**To learn more about AccuPlex SARS-CoV-2 Quality Solutions visit:**

**[www.seracare.com/SARSCoV2](http://www.seracare.com/SARSCoV2) or contact customer service at 800.676.1881**

## ABOUT LGC SERACARE


TRUSTED SUPPLIER  
TO THE DIAGNOSTIC  
TESTING INDUSTRY  
FOR OVER 30 YEARS

HIGH-QUALITY  
CONTROL PRODUCTS,  
RAW BIOLOGICAL  
MATERIALS, AND  
IMMUNOASSAY  
REAGENTS

INNOVATIVE TOOLS  
AND TECHNOLOGIES  
TO PROVIDE  
ASSURANCE IN  
DIAGNOSTIC ASSAY  
PERFORMANCE AND  
TEST RESULTS

FOR MORE  
INFORMATION, PLEASE  
VISIT OUR WEBSITE:  
[WWW.SERACARE.COM](http://WWW.SERACARE.COM)

LGC SeraCare's AccuPlex recombinant material serves as a true full process molecular control for your diagnostic assays. Compatible with multiplexed RT-PCR and NGS-based assays, AccuPlex custom recombinant materials are constructed with a replication-deficient mammalian virus, producing a safe, non-infectious material (Figure 1). With a protein coat and lipid bilayer, these mammalian virus-based reference materials resemble the complexity of virus targets found in true patient samples.



**FIGURE 1:** 1) RNA sequence from the pathogenic virus of interest is chosen. 2) DNA synthesis and cloning occur to produce the recombinant RNA. 3) Recombinant RNA and helper RNA are co-transfected into the mammalian cells, allowing the encapsulation of recombinant RNA. 4) Exocytosis of the mature enveloped non-infectious and replication deficient RNA virus containing the assay target RNA sequence of interest

## MOST 'PATIENT SAMPLE-LIKE' MATERIAL EVALUATES ENTIRE WORKFLOW

Unlike RNA-spiked buffer, or technologies that package viral RNA into a bacteriophage, the AccuPlex recombinant closely resembles the wild-type mammalian pathogenic virus. This enables the release of the viral genome at a similar rate to the wild-type virus during the nucleic acid sample preparation process. AccuPlex recombinant material mimics a real patient sample in your workflow, serving as a full-process control for your assay.

## ACCUPLEX SOLVES ASSAY DEVELOPMENT CHALLENGES

If you're developing diagnostics for emerging viral diseases and have the challenge of including safe, non-infectious controls in your test kit, partner with LGC SeraCare's talented R&D team to produce your custom AccuPlex recombinant virus material (DNA or RNA-based). Utilizing your sequences of interest and product specifications, we will develop a custom solution which meets your unique requirements.

## ORDERING INFORMATION

To place an order, or learn more about our SARS-CoV-2 Quality Solutions, please contact us at +1.508.244.6400 and 800.676.1881 or email [customerservice@seracare.com](mailto:customerservice@seracare.com).



AccuPlex™ is a trademark of SeraCare Life Sciences, Inc.  
© 2021 SeraCare Life Sciences, Inc. All rights reserved.  
MKT-00608